Previous close | 3.1500 |
Open | 2.9800 |
Bid | 3.5000 |
Ask | 4.4500 |
Strike | 310.00 |
Expiry date | 2024-07-19 |
Day's range | 2.9500 - 3.2500 |
Contract range | N/A |
Volume | |
Open interest | 648 |
Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit revenue growth. The biotechnology company's adjusted profit fell 1% to $3.96 per share, which still beat the average analyst estimate of $3.88 per share, according to LSEG data. The results were "essentially in-linish ... although not anything significant for the Street given that it is still early in the year," David Song, portfolio manager of the Tema Obesity & Cardiometabolic ETF said in an email.
Amgen stock popped late Thursday despite its profit beat as investors watch its potential rivals to Lilly and Novo drugs.